Armstrong, April http://orcid.org/0000-0003-0064-8707
Hahn-Pedersen, Julie http://orcid.org/0000-0001-8187-7047
Bartlett, Chris
Glanville, Julie http://orcid.org/0000-0002-1253-8524
Thyssen, Jacob P. http://orcid.org/0000-0003-3770-1743
Funding for this research was provided by:
leo pharma a/s
Article History
Accepted: 13 December 2021
First Online: 8 March 2022
Declarations
:
: The authors disclose receipt of financial support from Leo Pharma A/S for the research, authorship, and publication of this article.
: Jacob Thyssen has been an advisor/investigator or speaker for Abbvie, Pfizer, LEO Pharma, Regeneron, Sanofi Genzyme and Eli Lilly & Co. Julie Hahn-Pedersen is a former employee of LEO Pharma, who sponsored this review. Chris Bartlett (and formerly, Julie Glanville) is employed by York Health Economics Consortium, which received funding from LEO Pharma to conduct this review. April Armstrong has served as a research investigator or consultant to AbbVie, ASLAN, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: CB and JG developed the protocol, including formulation of the search strategy, managed the review production and contributed to data interpretation, and were also involved in drafting the manuscript. CB, JG, JH-P, AA and JT approved the final version for submission and agree to be accountable for all aspects of the work.